Immix Biopharma (IMMX) Other Working Capital Changes (2021 - 2026)

Immix Biopharma has reported Other Working Capital Changes for 3 years, with the latest figure at -$35229.0 in Q1 2026.

• Quarterly Other Working Capital Changes fell 122.59% year-over-year to -$35229.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117408.0 (down 242.45% YoY) and the FY2025 annual result came in at -$98006.0, down 3536.4% from the prior year.
• Other Working Capital Changes slipped to -$35229.0 in Q1 2026 per IMMX's latest filing, from -$33371.0 in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $1.3 million in Q2 2023 and troughed at -$1.0 million in Q4 2023.
• A 5-year average of $69279.9 and a median of $20418.0 in 2024 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2025 and 2026: Other Working Capital Changes tumbled 1450.4% in 2025, then plunged 122.59% in 2026.
• Over 3 years, Other Working Capital Changes stood at -$14285.0 in 2024, then sank by 133.61% to -$33371.0 in 2025, then retreated by 5.57% to -$35229.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$35229.0, -$33371.0, and -$32667.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.